Brain Stress Pathway Linked to Angelman Syndrome Offers New Therapeutic Targets

Angelman syndrome is caused by a change to a single gene.

Angelman syndrome, a neurodevelopmental disorder affecting roughly one in 20,000 births, produces a constellation of symptoms that emerge in early childhood. These include delayed speech, uncoordinated movement, seizures, frequent laughter or smiling, short attention spans, reduced sleep needs, and a pronounced fascination with water. Despite this complex clinical picture, the genetic cause is strikingly simple: the loss of a single gene, ubiquitin protein ligase E3A (UBE3A).

Researchers have long sought to bridge the gap between this missing gene and the syndrome’s diverse symptoms. A new study published in Nature by a team at Washington University reveals how UBE3A initiates a biochemical cascade that triggers a cellular stress response in the brain during a critical developmental window, stunting neural growth. The researchers demonstrated that lowering the levels of an enzyme downstream of UBE3A reversed many symptoms in mouse models, pointing toward a promising therapeutic avenue.

UBE3A Triggers a Biological Stress Response

Led by neuroscientist Jason Yi, the team investigated UBE3A’s function in cells and mice. Using liquid chromatography tandem mass spectrometry, they identified 23 proteins interacting with UBE3A, a ubiquitin ligase that tags proteins for degradation. One interaction stood out: asparagine synthetase (ASNS), an enzyme that synthesizes a non-essential amino acid. The gene encoding ASNS (ASNS) showed enrichment patterns in neurons similar to UBE3A.

In genetically modified mice lacking UBE3A, ASNS protein levels rose significantly. This elevation activated a stress response in brain cells. While elevated ASNS did not cause overt cellular damage, it resulted in brains that were measurably smaller than those of control mice—a hallmark of Angelman syndrome in humans.

“It’s a reaction from the brain trying to conserve resources to protect itself,” Yi explained. “It does suggest that there is a dysregulation in the brain we might be able to correct.” Normalizing ASNS levels restored typical brain size in the model mice and reversed certain behavioral anomalies, such as marble-burying patterns, though it did not correct sleep disturbances. This indicates that distinct behavioral features of the syndrome may be differentially linked to ASNS dysregulation.

Mapping the Stress Response Cascade

The precise mechanism by which elevated ASNS triggers the brain’s stress alarm remains unclear, but the findings establish a framework for targeting this stress response to alleviate symptoms.

“We still don’t know a whole lot about the disease,” Yi noted. “We haven’t been able to identify all of the things that the missing gene is doing and rescue the things that it is not doing in Angelman syndrome. But I think our data are the most complete so far to begin answering those questions.”

Source link